Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consum… Read more
Standard Biotools Inc (LAB) - Net Assets
Latest net assets as of September 2025: $399.66 Million USD
Based on the latest financial reports, Standard Biotools Inc (LAB) has net assets worth $399.66 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($539.64 Million) and total liabilities ($139.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $399.66 Million |
| % of Total Assets | 74.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | 239.25% |
| 10-Year Change | 310.55% |
| Growth Volatility | 85.44 |
Standard Biotools Inc - Net Assets Trend (2006–2024)
This chart illustrates how Standard Biotools Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Standard Biotools Inc (2006–2024)
The table below shows the annual net assets of Standard Biotools Inc from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $471.72 Million | +418.62% |
| 2023-12-31 | $-148.05 Million | -81.73% |
| 2022-12-31 | $-81.47 Million | -186.12% |
| 2021-12-31 | $94.60 Million | -31.97% |
| 2020-12-31 | $139.05 Million | -9.48% |
| 2019-12-31 | $153.61 Million | +113.01% |
| 2018-12-31 | $72.12 Million | +133.12% |
| 2017-12-31 | $30.93 Million | -41.89% |
| 2016-12-31 | $53.23 Million | -53.67% |
| 2015-12-31 | $114.90 Million | -23.61% |
| 2014-12-31 | $150.42 Million | +54.88% |
| 2013-12-31 | $97.12 Million | -3.52% |
| 2012-12-31 | $100.66 Million | +76.91% |
| 2011-12-31 | $56.90 Million | +130.08% |
| 2010-12-31 | $-189.17 Million | -8.96% |
| 2009-12-31 | $-173.62 Million | -9.65% |
| 2008-12-31 | $-158.34 Million | -21.49% |
| 2007-12-31 | $-130.33 Million | -22.75% |
| 2006-12-31 | $-106.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Standard Biotools Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 107737900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $396.00K | 0.08% |
| Other Comprehensive Income | $1.23 Million | 0.26% |
| Other Components | $1.66 Billion | 351.00% |
| Total Equity | $471.72 Million | 100.00% |
Standard Biotools Inc Competitors by Market Cap
The table below lists competitors of Standard Biotools Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ji-Haw Industrial Co Ltd
TW:3011
|
$41.49 Million |
|
SouthGobi Resources Ltd
PINK:SGQRF
|
$41.50 Million |
|
Integrated Wellness Acquisition Corp
NYSE:WEL
|
$41.50 Million |
|
OHARA INC.
F:9IE
|
$41.51 Million |
|
Kangda International Environmental Company Limited
STU:27K
|
$41.48 Million |
|
Vivani Medical Inc.
NASDAQ:VANI
|
$41.46 Million |
|
FTAC Emerald Acquisition Corp.
NASDAQ:FLDDU
|
$41.45 Million |
|
Mobilicom Limited American Depositary Shares
NASDAQ:MOB
|
$41.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Standard Biotools Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -148,051,000 to 471,722,000, a change of 619,773,000.
- Net loss of 138,885,000 reduced equity.
- Share repurchases of 40,949,000 reduced equity.
- Other comprehensive income increased equity by 3,446,000.
- Other factors increased equity by 796,161,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-138.88 Million | -29.44% |
| Share Repurchases | $40.95 Million | -8.68% |
| Other Comprehensive Income | $3.45 Million | +0.73% |
| Other Changes | $796.16 Million | +168.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Standard Biotools Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.74x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $-56.18 | $0.98 | x |
| 2007-12-31 | $-68.96 | $0.98 | x |
| 2008-12-31 | $-95.79 | $0.98 | x |
| 2009-12-31 | $-100.01 | $0.98 | x |
| 2010-12-31 | $-9.97 | $0.98 | x |
| 2011-12-31 | $3.19 | $0.98 | x |
| 2012-12-31 | $4.55 | $0.98 | x |
| 2013-12-31 | $3.81 | $0.98 | x |
| 2014-12-31 | $5.42 | $0.98 | x |
| 2015-12-31 | $4.00 | $0.98 | x |
| 2016-12-31 | $1.84 | $0.98 | x |
| 2017-12-31 | $0.94 | $0.98 | x |
| 2018-12-31 | $1.82 | $0.98 | x |
| 2019-12-31 | $2.30 | $0.98 | x |
| 2020-12-31 | $1.93 | $0.98 | x |
| 2021-12-31 | $1.25 | $0.98 | x |
| 2022-12-31 | $-1.04 | $0.98 | x |
| 2023-12-31 | $-1.87 | $0.98 | x |
| 2024-12-31 | $1.34 | $0.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Standard Biotools Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -79.62%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.30x
- Recent ROE (-29.44%) is above the historical average (-39.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | -368.13% | 0.18x | 0.00x | $-12.94 Million |
| 2007 | 0.00% | -349.84% | 0.13x | 0.00x | $-12.42 Million |
| 2008 | 0.00% | -192.21% | 0.47x | 0.00x | $-13.67 Million |
| 2009 | 0.00% | -75.27% | 0.79x | 0.00x | $-1.77 Million |
| 2010 | 0.00% | -50.36% | 1.35x | 0.00x | $2.01 Million |
| 2011 | -39.49% | -52.42% | 0.54x | 1.39x | $-28.16 Million |
| 2012 | -18.90% | -36.35% | 0.46x | 1.13x | $-29.09 Million |
| 2013 | -16.29% | -22.23% | 0.61x | 1.20x | $-25.53 Million |
| 2014 | -35.12% | -45.36% | 0.29x | 2.71x | $-67.87 Million |
| 2015 | -46.40% | -46.48% | 0.31x | 3.23x | $-64.81 Million |
| 2016 | -142.74% | -72.75% | 0.34x | 5.76x | $-81.31 Million |
| 2017 | -195.68% | -59.38% | 0.35x | 9.29x | $-63.63 Million |
| 2018 | -81.83% | -52.24% | 0.37x | 4.21x | $-66.22 Million |
| 2019 | -42.18% | -55.26% | 0.44x | 1.72x | $-80.15 Million |
| 2020 | -38.13% | -38.38% | 0.43x | 2.34x | $-66.92 Million |
| 2021 | -62.62% | -45.36% | 0.47x | 2.91x | $-68.70 Million |
| 2022 | 0.00% | -194.08% | 0.25x | 0.00x | $-181.95 Million |
| 2023 | 0.00% | -70.21% | 0.33x | 0.00x | $-59.85 Million |
| 2024 | -29.44% | -79.62% | 0.28x | 1.30x | $-186.06 Million |
Industry Comparison
This section compares Standard Biotools Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Standard Biotools Inc (LAB) | $399.66 Million | 0.00% | 0.35x | $41.48 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |